These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19276671)

  • 21. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W; Kim H; Ho M
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel semi-mechanistic tumor growth fraction model for translation of preclinical efficacy of anti-glypican 3 antibody drug conjugate to human.
    Singh R; Kozhich A; Pan C; Lee F; Cardarelli P; Vangipuram R; Iyer R; Marathe P
    Biopharm Drug Dispos; 2020 Nov; 41(8-9):319-333. PubMed ID: 32678919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.
    Zhang M; Wen B; Anton OM; Yao Z; Dubois S; Ju W; Sato N; DiLillo DJ; Bamford RN; Ravetch JV; Waldmann TA
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10915-E10924. PubMed ID: 30373815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
    Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma.
    Takai H; Ashihara M; Ishiguro T; Terashima H; Watanabe T; Kato A; Suzuki M
    Cancer Biol Ther; 2009 Dec; 8(24):2329-38. PubMed ID: 19838081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
    Feng M; Gao W; Wang R; Chen W; Man YG; Figg WD; Wang XW; Dimitrov DS; Ho M
    Proc Natl Acad Sci U S A; 2013 Mar; 110(12):E1083-91. PubMed ID: 23471984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
    Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
    J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A monoclonal antibody recognizing CD98 on human embryonic stem cells shows anti-tumor activity in hepatocellular carcinoma xenografts.
    Lim K; Han SH; Han S; Lee JY; Choi HS; Choi D; Ryu CJ
    Cancer Immunol Immunother; 2024 Sep; 73(11):231. PubMed ID: 39261363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma.
    Xia L; Teng Q; Chen Q; Zhang F
    Int J Nanomedicine; 2020; 15():2197-2205. PubMed ID: 32280214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
    Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
    Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.
    Hanaoka H; Nagaya T; Sato K; Nakamura Y; Watanabe R; Harada T; Gao W; Feng M; Phung Y; Kim I; Paik CH; Choyke PL; Ho M; Kobayashi H
    Mol Pharm; 2015 Jun; 12(6):2151-7. PubMed ID: 25955255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma.
    Yu L; Huang N; Sun H; Yang X; Fu Y; Lang Q; Wang J; Ge L
    J Immunother; 2021 Apr; 44(3):106-113. PubMed ID: 33239522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
    Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
    FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma.
    Yorita K; Takahashi N; Takai H; Kato A; Suzuki M; Ishiguro T; Ohtomo T; Nagaike K; Kondo K; Chijiiwa K; Kataoka H
    Liver Int; 2011 Jan; 31(1):120-31. PubMed ID: 20964802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.
    Wang C; Gao W; Feng M; Pastan I; Ho M
    Oncotarget; 2017 May; 8(20):32450-32460. PubMed ID: 27419635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
    Phung Y; Gao W; Man YG; Nagata S; Ho M
    MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.
    Xiao Z; Chung H; Banan B; Manning PT; Ott KC; Lin S; Capoccia BJ; Subramanian V; Hiebsch RR; Upadhya GA; Mohanakumar T; Frazier WA; Lin Y; Chapman WC
    Cancer Lett; 2015 May; 360(2):302-9. PubMed ID: 25721088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
    Barok M; Isola J; Pályi-Krekk Z; Nagy P; Juhász I; Vereb G; Kauraniemi P; Kapanen A; Tanner M; Vereb G; Szöllösi J
    Mol Cancer Ther; 2007 Jul; 6(7):2065-72. PubMed ID: 17620435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.